Skip to main content

ESC Guidelines - Congenital AV Block – Pacing Indications

 

Congenital AV Block – Pacing Indications

Congenital atrioventricular (AV) block may be isolated (often immune-mediated due to maternal anti-Ro/SSA or anti-La antibodies) or associated with structural heart disease (e.g., congenitally corrected TGA). Pacing decisions depend on symptoms, ventricular rate, ventricular function, and risk markers.



---


1. Class I Indications (Permanent Pacemaker Recommended)


1. Symptomatic bradycardia


Syncope, presyncope


Heart failure


Exercise intolerance




2. Asymptomatic complete (3rd-degree) AV block with:


Wide QRS escape rhythm


Ventricular dysfunction


Complex ventricular ectopy


Prolonged QT interval




3. Neonates/Infants with complete AV block and:


Ventricular rate <55 bpm


Ventricular rate <70 bpm if associated with congenital heart disease




4. Postoperative advanced AV block


Persisting >7–10 days after congenital cardiac surgery






---


2. Class IIa Indications (Reasonable to Pace)


1. Asymptomatic complete AV block beyond infancy with:


Average heart rate <50 bpm


Pauses >3 seconds


Chronotropic incompetence




2. Progressive ventricular dilation or declining LV function even if asymptomatic.



3. Neuromuscular diseases associated with AV block (e.g., Kearns-Sayre syndrome, Emery-Dreifuss muscular dystrophy).





---


3. Class IIb (May Be Considered)


Asymptomatic adolescents or adults with congenital complete AV block and acceptable escape rhythm but:


Resting HR persistently <50 bpm


Subtle LV dysfunction


Prolonged pauses during sleep





---


Important Risk Markers for Sudden Death


Even asymptomatic patients may need pacing if they have:


Ventricular rate <50 bpm


Wide QRS escape rhythm


Ventricular ectopy


LV dilation or dysfunction


Prolonged QT


Complex ventricular arrhythmias




---


Special Considerations


Fetal Complete AV Block


Diagnosed by fetal echocardiography (M-mode).


If ventricular rate <55 bpm → high risk of hydrops and mortality.


Maternal steroids sometimes used in immune-mediated cases.


Postnatal pacing frequently required.



Site of Pacing


Neonates/infants → often epicardial systems


Older children/adolescents → transvenous dual-chamber pacing preferred


Consider physiologic pacing (His bundle/LBB pacing) when feasible to avoid pacing-induced cardiomyopathy.




---


Practical Clinical Pearls


Congenital complete AV block patients can remain asymptomatic for years — but progressive LV dysfunction is common, hence periodic echo is essential.


Nighttime bradycardia alone is not always an indication unless associated with long pauses.


Dual-chamber pacing is generally preferred to preserve AV synchrony.

Drmusmanjaved.com


Comments

  1. I was diagnosed with Idiopathic Pulmonary Fibrosis (IPF) four years ago. For over two years, I relied on prescribed medications and treatments, but unfortunately, my condition continued to worsen. My breathing became more difficult, fatigue increased, and even simple activities started to leave me exhausted.Last year, out of desperation and hope, I decided to try a herbal treatment program from NaturePath Herbal Clinic. Honestly, I was skeptical at first, but within a few months of starting the treatment, I began to notice real changes. My breathing improved, my energy levels increased, and I was able to do more without feeling constantly short of breath.It’s been a life-changing experience I feel more like myself again, better than I’ve felt in years. If you or a loved one is struggling with IPF, I truly recommend looking into their natural approach. You can visit their website at www.naturepathherbalclinic.com
    or contact them at info@naturepathherbalclinic.com

    ReplyDelete

Post a Comment

Drop your thoughts here, we would love to hear from you

Popular posts from this blog

π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š

 π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...

2025 AHA/ACC Hypertension Guidelines Key points

  2025 AHA/ACC Hypertension Guidelines Explained: A Clear Summary for Clinicians and Students Hypertension remains one of the most significant contributors to cardiovascular morbidity and mortality worldwide. With continual refinement of evidence and risk-based strategies, the 2025 AHA/ACC Hypertension Guidelines bring an updated, practical approach that clinicians can use in daily practice. To make learning easier, I’ve created a clean and modern infographic summarizing all major recommendations. You can download it below and use it for study, teaching, or clinical reference. Download Infographic (PNG): 2025 Hypertension Guideline Infographic This post breaks down the key points from the guidelines and complements the infographic for a complete understanding. --- BP Categories: Understanding the Updated Thresholds The guidelines maintain the well-established classification of blood pressure: Normal: <120 / <80 Elevated: 120–129 / <80 Stage 1 Hypertension: 130–139 and/or 8...